Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

• Status: Recruiting
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: Female

Summary

To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rajavithi Hospital
• Treatments: Carboplatin; Olanzapine

Criteria

Inclusion Criteria:

• Women with gynecological cancer receiving carboplatin-based chemotherapeutic regimen

• ECOG performance status 0-1

• Normal bone marrow, liver, and renal functions

• Can speak and write in Thai language

Exclusion Criteria:

• Women with nausea or vomiting prior to chemotherapeutic administration

• Pregnant women

• Women with active infection

• Women with bowel obstruction

• Women with symptomatic brain metastases

• Women who received dopamine receptor antagonists within 1 week before chemotherapeutic administration

• Women who received corticosteroid within 1 week before chemotherapeutic administration

• Women with past history of chemotherapy or radiotherapy

• Women with psychiatric disorders

• Women with poor controlled diabetes mellitus

• Women who received anticonvulsant medication

• Women with history of neuroleptic malignant syndrome

• Women with history of olanzapine allergy

• Women with history of lactose intolerance